Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04320342 · ClinicalTrials.gov registry record · Phase 3
A Study Comparing Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination CHF 5993 With the Fixed Dose Dual Combination CHF 1535 in Subjects With COPD
A Phase 3 study, sponsored by Chiesi Farmaceutici S.p.A..
- Completed
- Registry status
- Phase 3
- Development phase
- 3,433
- Enrollment target
NCT04320342 is a Phase 3 study that has completed, run by Chiesi Farmaceutici S.p.A.. The registered enrollment target is 3,433 participants.
The verdict
NCT04320342, a Phase 3 study, has completed, sponsored by Chiesi Farmaceutici S.p.A..
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 3,433 participants
- Enrollment target
Study Summary
The purpose of this study is to compare CHF 5993 with CHF 1535 in improving lung function, reducing moderate and severe COPD exacerbations, and other clinical efficacy and safety outcomes in the target subject population.
Interventions
- DRUG Formoterol Fumarate
- DRUG Beclomethasone Dipropionate
- DRUG Glycopyrronium Bromide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3,433 participants |
| Start Date | 2022-04-28 |
| Est. Completion | 2026-01-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04320342
The ClinicalTrials.gov registry entry for NCT04320342 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 3,433 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Chiesi Farmaceutici S.p.A., which has 30 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Formoterol Fumarate is the first listed.
NCT04320342 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04320342 about?
NCT04320342 is a clinical study titled "A Study Comparing Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination CHF 5993 With the Fixed Dose Dual Combination CHF 1535 in Subjects With COPD". The purpose of this study is to compare CHF 5993 with CHF 1535 in improving lung function, reducing moderate and severe COPD exacerbations, and other clinical efficacy and safety outcomes in the target subject population.
What is the current status of trial NCT04320342?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 3,433 participants. The study started on 2022-04-28. Estimated completion is 2026-01-12.
What interventions are being tested in trial NCT04320342?
The interventions under investigation include: Formoterol Fumarate (DRUG), Beclomethasone Dipropionate (DRUG), Glycopyrronium Bromide (DRUG).
Who is sponsoring clinical trial NCT04320342?
This trial is sponsored by Chiesi Farmaceutici S.p.A., which has 30 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.